HUTCHMED (China) Limited (H7T1) - Net Assets

Latest as of December 2025: €1.25 Billion EUR ≈ $1.46 Billion USD

Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has net assets worth €1.25 Billion EUR (≈ $1.46 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.75 Billion ≈ $2.05 Billion USD) and total liabilities (€501.83 Million ≈ $586.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is HUTCHMED (China) Limited's equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets €1.25 Billion
% of Total Assets 71.37%
Annual Growth Rate 22.33%
5-Year Change 20.37%
10-Year Change N/A
Growth Volatility 56.98

HUTCHMED (China) Limited - Net Assets Trend (2016–2025)

This chart illustrates how HUTCHMED (China) Limited's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of HUTCHMED (China) Limited to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for HUTCHMED (China) Limited (2016–2025)

The table below shows the annual net assets of HUTCHMED (China) Limited from 2016 to 2025. For live valuation and market cap data, see HUTCHMED (China) Limited stock valuation.

Year Net Assets Change
2025-12-31 €1.25 Billion
≈ $1.46 Billion		 +62.11%
2024-12-31 €771.85 Million
≈ $902.38 Million		 +3.83%
2023-12-31 €743.39 Million
≈ $869.10 Million		 +16.73%
2022-12-31 €636.87 Million
≈ $744.57 Million		 -38.73%
2021-12-31 €1.04 Billion
≈ $1.22 Billion		 +100.31%
2020-12-31 €518.95 Million
≈ $606.71 Million		 +65.85%
2019-12-31 €312.90 Million
≈ $365.82 Million		 -24.10%
2018-12-31 €412.25 Million
≈ $481.97 Million		 -14.99%
2017-12-31 €484.97 Million
≈ $566.98 Million		 +137.66%
2016-12-31 €204.06 Million
≈ $238.57 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to HUTCHMED (China) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 29828600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components €1.62 Billion 130.59%
Total Equity €1.24 Billion 100.00%

HUTCHMED (China) Limited Competitors by Market Cap

The table below lists competitors of HUTCHMED (China) Limited ranked by their market capitalization.

Company Market Cap
OFG Bancorp
NYSE:OFG
 $1.84 Billion
Alamo Group Inc
NYSE:ALG
 $1.84 Billion
Punjab & Sind Bank
NSE:PSB
 $1.84 Billion
Investec Ltd
JSE:INL
 $1.84 Billion
BaoViet Holdings
VN:BVH
 $1.84 Billion
ProPetro Holding Corp
NYSE:PUMP
 $1.84 Billion
IBI Inv House
TA:IBI
 $1.84 Billion
Central China Land Media Co Ltd
SHE:000719
 $1.84 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in HUTCHMED (China) Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 759,929,000 to 1,237,926,000, a change of 477,997,000 (62.9%).
  • Net income of 456,909,000 contributed positively to equity growth.
  • New share issuances of 1,578,000 increased equity.
  • Other factors increased equity by 19,510,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €456.91 Million +36.91%
Share Issuances €1.58 Million +0.13%
Other Changes €19.51 Million +1.58%
Total Change €- 62.90%

Book Value vs Market Value Analysis

This analysis compares HUTCHMED (China) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 6.35x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 13.17x to 6.35x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €0.69 €9.15 x
2018-12-31 €0.58 €9.15 x
2019-12-31 €0.43 €9.15 x
2020-12-31 €0.67 €9.15 x
2021-12-31 €1.14 €9.15 x
2022-12-31 €0.71 €9.15 x
2023-12-31 €0.86 €9.15 x
2024-12-31 €0.89 €9.15 x
2025-12-31 €1.44 €9.15 x

Capital Efficiency Dashboard

This dashboard shows how efficiently HUTCHMED (China) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 36.91%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 83.30%
  • • Asset Turnover: 0.31x
  • • Equity Multiplier: 1.42x
  • Recent ROE (36.91%) is above the historical average (-10.46%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 6.35% 5.41% 0.63x 1.86x €-6.73 Million
2017 -5.79% -11.08% 0.40x 1.29x €-72.91 Million
2018 -19.23% -34.94% 0.40x 1.37x €-113.70 Million
2019 -36.81% -51.75% 0.44x 1.61x €-134.83 Million
2020 -25.97% -55.15% 0.31x 1.50x €-174.14 Million
2021 -19.72% -54.66% 0.26x 1.39x €-293.34 Million
2022 -59.12% -84.62% 0.41x 1.69x €-421.87 Million
2023 13.80% 12.03% 0.65x 1.75x €27.73 Million
2024 4.96% 5.99% 0.49x 1.68x €-38.26 Million
2025 36.91% 83.30% 0.31x 1.42x €333.12 Million

Industry Comparison

This section compares HUTCHMED (China) Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $6,711,906,287
  • Average return on equity (ROE) among peers: -52.40%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
HUTCHMED (China) Limited (H7T1) €1.25 Billion 6.35% 0.40x $1.84 Billion
SHANG.FOS.PHARM.GR.H YC 1 (08HH) $59.93 Billion 4.62% 0.96x $1.14 Billion
PEPTONIC MEDICAL (28L) $53.12 Million -138.73% 0.59x $4.14 Million
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) $6.65 Billion 14.85% 0.54x $692.11 Million
WEST ISLAND BRANDS INC. (39N0) $3.27 Million -157.21% 0.88x $1.34 Million
AYURCANN HOLDINGS CORP. (3ZQ0) $2.69 Million -197.11% 3.73x $97.35K
CERENO SCIENTIFIC AB B (4A1) $252.47 Million -46.64% 0.59x $157.72 Million
MAPLE LEAF GREEN WORLD (4HV0) $-8.83 Million 0.00% 0.00x $504.30K
LORDS CO. WORLDW. HOLD. (4XM) $-1.01 Million 0.00% 0.00x $134.78K
RED LIGHT HOLLAND CORP. (4YX) $17.35 Million -23.30% 0.22x $13.93 Million
EQL PHARMA AB (7JK) $221.03 Million 19.51% 2.66x $78.02 Million

About HUTCHMED (China) Limited

F:H7T1 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$1.84 Billion
€1.57 Billion EUR
Market Cap Rank
#6591 Global
#962 in Germany
Share Price
€9.15
Change (1 day)
+0.55%
52-Week Range
€9.00 - €15.90
All Time High
€36.80
Categories
Companies in Germany Drug Manufacturers - Specialty & Generic
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more